Companies · Pharmaceuticals

Earth Science Tech, Inc.

MIAMI · Pharmaceuticals

Diligence memoA one-page analyst read on Earth Science Tech, Inc. — recommendation, valuation, rhythm, risks.
$2.8M
Total raised · real
4
Rounds
0.5×
Latest step-up
Top 69%
Sector rank · raised
Seed
Latest stage · inferred · Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Earth Science Tech, Inc. looks fair against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.81× the median modeled value of Seed Pharmaceuticals companies in 2022–2024 (50 peers) — value vs value, same stage and era.
  • Within the normal band (81% of peer median) for its niche.
At-risk
  • Last raise 3.7 yr ago; this sector typically re-raises about every 13 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Earth Science Tech, Inc. is one of 1613 Pharmaceuticals companies tracked from MIAMI. By capital raised it ranks in the long tail (ahead of 32% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
$5M–$25M
Issuer revenue
Rule 506(b)
Reg D exemption
62
Investors (latest)
2022-10-18
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MPre-Seed · 2018-04-02 Raised $498K (real) Modeled valuation $24M (est)$498K$24MPre-Seed2018Pre-Seed · 2022-06-10 Raised $350K (real) Modeled valuation $5.3M (est)$350K$5.3MPre-Seed2022Seed · 2022-10-08 Raised $1.2M (real) Modeled valuation $14M (est)$1.2M$14MSeed2022Seed · 2022-10-18 Raised $674K (real) Modeled valuation $7.8M (est)$674K$7.8MSeed2022+$350K+$1.2M+$674KCumulative $2.8M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$498K · 2018
Pre-Seed extension$350K · 2022
Seed$1.2M · 2022
Seed extension$674K · 2022

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$7.8M
Base estimate est.
$510K
Conservative case
$32.8M
Upside case
$3.4M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $23.5M · 2018-04-022018Pre-Seed · modeled $5.3M · 2022-06-10Seed · modeled $14.4M · 2022-10-08Seed · modeled $7.8M · 2022-10-182022
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
34%
Survival probability
15% low · 52% high
1.68×/yr
Annual markup
2.20×/yr upside case
3.7 yr
Elapsed time used
3.7 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
18 mo
Avg between rounds
$606K/yr
Capital velocity
8.3 yr
On record since
2018
First round
4
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.3× of median
This company$2.8M
Sector median$8.1M
Latest round — vs other Seed rounds in sector (real $, this stage) 0.4× of median
This company$674K
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 0.1× of median
This company$7.8M
Sector median$76.1M

Raised more than 32% of sector peers (real $). Modeled value above 13% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #30 of 50.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0M$10.0MCapital raised (log)Celeris Therapeutics, Inc. · Seed Raised $3.0M · modeled $48.7M (est)Oligomerix, Inc. · Seed Raised $8.3M · modeled $37.8M (est)2A Biosciences, Inc. · Seed Raised $3.8M · modeled $36.0M (est)Myosin Therapeutics Inc. · Seed Raised $3.0M · modeled $32.4M (est)Eluciderm Inc. · Seed Raised $3.8M · modeled $31.7M (est)AION Healthspan, Inc. · Seed Raised $2.9M · modeled $28.5M (est)Cannabinoid API Solutions, LLC · Seed Raised $2.2M · modeled $27.4M (est)CanaQuest Medical Corp. · Seed Raised $2.0M · modeled $22.8M (est)M Chest Institutional Pharmacy Group, LLC · Seed Raised $3.7M · modeled $21.4M (est)Vitalis Therapeutics, Inc. · Seed Raised $2.0M · modeled $20.8M (est)Visiox Pharma, LLC · Seed Raised $1.3M · modeled $17.5M (est)Adtech Pharma, Inc. · Seed Raised $3.0M · modeled $17.0M (est)Earth Science Tech, Inc. (this company) Raised $2.8M · modeled $7.8M (est)Earth Science Tech, Inc.
CompanyStageRaised · realValue · estvs peer med.
Celeris Therapeutics, Inc.Seed$3.0M$48.7M5.06×
Oligomerix, Inc.Seed$8.3M$37.8M3.93×
2A Biosciences, Inc.Seed$3.8M$36.0M3.74×
Myosin Therapeutics Inc.Seed$3.0M$32.4M3.37×
Eluciderm Inc.Seed$3.8M$31.7M3.29×
AION Healthspan, Inc.Seed$2.9M$28.5M2.96×
Cannabinoid API Solutions, LLCSeed$2.2M$27.4M2.85×
CanaQuest Medical Corp.Seed$2.0M$22.8M2.37×
M Chest Institutional Pharmacy Group, LLCSeed$3.7M$21.4M2.22×
Vitalis Therapeutics, Inc.Seed$2.0M$20.8M2.16×
Visiox Pharma, LLCSeed$1.3M$17.5M1.82×
Adtech Pharma, Inc.Seed$3.0M$17.0M1.76×
Earth Science Tech, Inc. this companySeed$2.8M$7.8M0.81×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$498K2018-04-02$2.8M$23.5M90%
Pre-Seed$350K2022-06-10$1.9M$5.3M90%
Seed$1.2M2022-10-08$6.2M$14.4M90%
Seed$674K2022-10-18$3.4M$7.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$498K2018-04-02
    • First recorded raise — entered as Pre-Seed.
    • 46 investors on this round.
  2. Pre-Seed$350K2022-06-10
    • Raised again after 50 mo — slower than the ~13 mo sector norm.
    • Round 1.4× smaller than the prior — bridge or down round.
    • Revenue band moved $0–$1M → $5M–$25M.
    • 1 investor on this round.
  3. Seed$1.2M2022-10-08
    • Came back fast: 4 mo vs the ~13 mo sector norm.
    • Round 3.5× larger than the prior — scaling up.
    • 9 investors on this round.
  4. Seed$674K2022-10-18
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.8× smaller than the prior — bridge or down round.
    • 62 investors on this round.
Intelligence
2024 ~Q2
Modeled next raise · ~18mo cadence
$674K
Modeled next size est.range $674K$1.1M
0.5×
Last step-up
$606K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Gagan S Hunter2018-04
Giorgio Ramon Saumat2022-10
Giorgio R Saumat2022-06
Jill S Buzan2018-04
Nickolas S Tabraue2018-04
Sergio S Castillo2018-04
Steven S Warm2018-04
Wendell S Hecker2018-04
Registry & provenance

Earth Science Tech, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1538495
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Nomocan Pharmaceuticals LlcPharmaceuticalsSeed$2.7M$3.4Msame sector · same stage
Xtresse, LlcPharmaceuticalsSeed$2.7M$6.5Msame sector · same stage
Mayne Pharma Group LtdPharmaceuticalsSeed$2.8M$5.4Msame sector · same stage
Doza Investments - Relox Medical, L.P.PharmaceuticalsSeed$2.7M$4.5Msame sector · same stage
TrippBio, Inc.PharmaceuticalsSeed$2.9M$10.8Msame sector · same stage
Gate Science Inc.PharmaceuticalsSeed$2.6M$1.7Msame sector · same stage
TheraVasc Inc.PharmaceuticalsSeed$2.6M$13.3Msame sector · same stage
Supreme Pharmaceuticals Inc.PharmaceuticalsSeed$2.9M$14.1Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Med-Tech Investments Group, LLCPharmaceuticalsSeed$98.9M82%
TF Tech Ventures, Inc.PharmaceuticalsPre-Seed$8.3M82%
Gate Science Inc.PharmaceuticalsSeed$1.7M82%
Land Medicine Inc.PharmaceuticalsSeries B$98.0M81%
Agile Sciences, IncPharmaceuticalsSeed$38.0M81%
Geode Therapeutics Inc.PharmaSeries A$162.6M81%
Solid Biosciences Inc.PharmaceuticalsSeries C$139.4M81%
Scienture Inc.PharmaceuticalsSeries A$185.8M80%
Frequently asked
How much funding has Earth Science Tech, Inc. raised?
Earth Science Tech, Inc. has raised approximately $2.8M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is Earth Science Tech, Inc.'s estimated valuation?
Provath's modeled valuation for Earth Science Tech, Inc. is approximately $7.8M (modeled range $510K–$32.8M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Earth Science Tech, Inc. at?
Earth Science Tech, Inc.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Tue Oct 18.
What does Earth Science Tech, Inc. do and where is it based?
Earth Science Tech, Inc. operates in the Pharmaceuticals sector, based in MIAMI.
Explore related

See where Earth Science Tech, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Earth Science Tech, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.